Cargando…

Prospects of a Transdermal Dosage Form (Microneedles) and Justification of the Active Substance Selection for Development of a New Medicine

Prospects for the development of a transdermal dosage form (DF) based on microneedles were considered. Methods for obtaining such systems, the application areas, and data from the pharmaceutical market were examined. A wide sample of INNs that are used to reduce pain in osteoarthritis patients was f...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogaeva, U. V., Leshkevich, A. A., Yurochkin, D. S., Golant, Z. M., Flisyuk, E. V., Ivkin, D. Yu.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810208/
https://www.ncbi.nlm.nih.gov/pubmed/35132286
http://dx.doi.org/10.1007/s11094-021-02541-7
_version_ 1784644202756308992
author Nogaeva, U. V.
Leshkevich, A. A.
Yurochkin, D. S.
Golant, Z. M.
Flisyuk, E. V.
Ivkin, D. Yu.
author_facet Nogaeva, U. V.
Leshkevich, A. A.
Yurochkin, D. S.
Golant, Z. M.
Flisyuk, E. V.
Ivkin, D. Yu.
author_sort Nogaeva, U. V.
collection PubMed
description Prospects for the development of a transdermal dosage form (DF) based on microneedles were considered. Methods for obtaining such systems, the application areas, and data from the pharmaceutical market were examined. A wide sample of INNs that are used to reduce pain in osteoarthritis patients was formed based on clinical guidelines. The market capacity, sales by Anatomical Therapeutic Chemical (ATC-2) groups, and sales depending on the DF were discussed. Criteria for the choice of active ingredients with market potential were defined. An analysis of a short list revealed that meloxicam has sufficient market potential to create a microneedle DF. A forecast of meloxicam consumption based on time series models indicated stable sales-growth dynamics and a potential market size of 4.6 billion Russian rubles by 2030. Results of the study indicated good market prospects and justification of pharmaceutical development of a new transdermal DF including meloxicam microneedles as the active ingredient.
format Online
Article
Text
id pubmed-8810208
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-88102082022-02-03 Prospects of a Transdermal Dosage Form (Microneedles) and Justification of the Active Substance Selection for Development of a New Medicine Nogaeva, U. V. Leshkevich, A. A. Yurochkin, D. S. Golant, Z. M. Flisyuk, E. V. Ivkin, D. Yu. Pharm Chem J Drug Synthesis Methods and Manufacturing Technology Prospects for the development of a transdermal dosage form (DF) based on microneedles were considered. Methods for obtaining such systems, the application areas, and data from the pharmaceutical market were examined. A wide sample of INNs that are used to reduce pain in osteoarthritis patients was formed based on clinical guidelines. The market capacity, sales by Anatomical Therapeutic Chemical (ATC-2) groups, and sales depending on the DF were discussed. Criteria for the choice of active ingredients with market potential were defined. An analysis of a short list revealed that meloxicam has sufficient market potential to create a microneedle DF. A forecast of meloxicam consumption based on time series models indicated stable sales-growth dynamics and a potential market size of 4.6 billion Russian rubles by 2030. Results of the study indicated good market prospects and justification of pharmaceutical development of a new transdermal DF including meloxicam microneedles as the active ingredient. Springer US 2022-02-03 2022 /pmc/articles/PMC8810208/ /pubmed/35132286 http://dx.doi.org/10.1007/s11094-021-02541-7 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Drug Synthesis Methods and Manufacturing Technology
Nogaeva, U. V.
Leshkevich, A. A.
Yurochkin, D. S.
Golant, Z. M.
Flisyuk, E. V.
Ivkin, D. Yu.
Prospects of a Transdermal Dosage Form (Microneedles) and Justification of the Active Substance Selection for Development of a New Medicine
title Prospects of a Transdermal Dosage Form (Microneedles) and Justification of the Active Substance Selection for Development of a New Medicine
title_full Prospects of a Transdermal Dosage Form (Microneedles) and Justification of the Active Substance Selection for Development of a New Medicine
title_fullStr Prospects of a Transdermal Dosage Form (Microneedles) and Justification of the Active Substance Selection for Development of a New Medicine
title_full_unstemmed Prospects of a Transdermal Dosage Form (Microneedles) and Justification of the Active Substance Selection for Development of a New Medicine
title_short Prospects of a Transdermal Dosage Form (Microneedles) and Justification of the Active Substance Selection for Development of a New Medicine
title_sort prospects of a transdermal dosage form (microneedles) and justification of the active substance selection for development of a new medicine
topic Drug Synthesis Methods and Manufacturing Technology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810208/
https://www.ncbi.nlm.nih.gov/pubmed/35132286
http://dx.doi.org/10.1007/s11094-021-02541-7
work_keys_str_mv AT nogaevauv prospectsofatransdermaldosageformmicroneedlesandjustificationoftheactivesubstanceselectionfordevelopmentofanewmedicine
AT leshkevichaa prospectsofatransdermaldosageformmicroneedlesandjustificationoftheactivesubstanceselectionfordevelopmentofanewmedicine
AT yurochkinds prospectsofatransdermaldosageformmicroneedlesandjustificationoftheactivesubstanceselectionfordevelopmentofanewmedicine
AT golantzm prospectsofatransdermaldosageformmicroneedlesandjustificationoftheactivesubstanceselectionfordevelopmentofanewmedicine
AT flisyukev prospectsofatransdermaldosageformmicroneedlesandjustificationoftheactivesubstanceselectionfordevelopmentofanewmedicine
AT ivkindyu prospectsofatransdermaldosageformmicroneedlesandjustificationoftheactivesubstanceselectionfordevelopmentofanewmedicine